[Expression of KiSS-1, matrix metalloproteinase-9, nuclear factor-kappaBp65 in ovarian tumour].
Gao. Guo-lan GL; Liu. Li-dan LD; Zou. Xue-sen XS; Chen. Wen-xue WX
Key Findings
- KiSS-1 (metastin) expression is higher in ovarian cancer tissue than in benign or normal ovarian tissue.
- Higher KiSS-1 levels are negatively correlated with MMP-9 and NF‑kappaB expression, both of which are linked to tumor invasion and metastasis.
- MMP-9 and NF‑kappaB levels increase with more advanced cancer stage and lymph node involvement.
Practical Outcomes
- For the biohacker community, this study does not offer actionable protocols, dosing, or safety data for kisspeptin supplementation. It simply suggests that kisspeptin might have anti‑cancer properties by dampening MMP-9 and NF‑kappaB, but translating this into real‑world use would require far more research.
Summary
The study looked at a protein called KiSS-1 (kisspeptin) in ovarian tumors and found that higher KiSS-1 levels are linked to lower levels of two other proteins, MMP-9 and NF‑kappaB, which are associated with cancer spread. While KiSS-1 may help suppress tumor metastasis, the research is limited to tissue samples and does not provide any guidance on how to use kisspeptin in everyday health or longevity practices.
Abstract
To investigate the expression and correlation of KiSS-1, matrix metalloproteinase-9 (MMP-9) and nuclear factor (NF)-kappaBp65 proteins in primary epithelial ovarian tumors. Expression of KiSS-1, MMP-9, NF-kappaBp65 proteins in primary ovarian epithelial tumors (malignant n = 50, borderline tumor n = 20, benign adenoma n = 20, normal tissue n = 10) was evaluated by immunohistochemical staining. Expression of metastin protein in primary epithelial ovarian cancers was significantly higher than that in ovarian benign adenoma (P < 0.05) and normal tissues (P < 0.05). Expression of metastin protein in ovarian borderline tumors was significantly higher than that in normal tissues (P < 0.05). Expression of metastin protein in ovarian cancer was significantly correlated with node metastasis (P < 0.05). However, Metastin protein expression was not correlated with different histological classifications (P > 0.05), differentiation grade (P > 0.05) and International Federation of Gynecology and Obstetrics (FIGO) stage (P > 0.05). MMP-9 protein was positive in 68% (34/50) of the epithelial ovarian cancers, significantly higher than that in normal tissues (20%, 2/10; P < 0.05). NF-kappaBp65 protein was positive in 72% (36/50) of the epithelial ovarian cancers, significantly higher than that in ovarian benign adenoma (30%, 6/20; P < 0.05) and normal tissues (10%, 1/10; P < 0.05). The expression of MMP-9 protein in epithelial ovarian cancer was significantly correlated with FIGO stage (P < 0.05) and lymph node metastasis (P < 0.05). However, MMP-9 protein expression was not correlated with different histological classifications (P > 0.05) and differentiation grade (P > 0.05). The expression of NF-kappaBp65 protein in epithelial ovarian cancer was significantly correlated with FIGO stage (P < 0.05), differentiation grade (P < 0.05) and lymph node metastasis (P < 0.05). However, NF-kappaBp65 protein expression was not correlated with different histological classifications (P > 0.05). There was obviously negative correlation between KiSS-1 and MMP-9 expression in ovarian cancer (rs = -0.547, P < 0.05), as well as between KiSS-1 and NF-kappaBp65 expression in ovarian cancer (rs = -0.414, P < 0.05), while there was obviously positive correlation between MMP-9 and NF-kappaBp65 expression in ovarian cancer (rs = 0.695, P < 0.05). The results indicate that KiSS-1 plays some role in suppression of the metastasis of ovarian epithelial cancers, which may be through inhibiting the expression of MMP-9 and NF-kappaBp65.
Study Information
pubmed
2007